Biognosys AG

Biognosys is a global leader in proteomics, offering next-generation protein analysis solutions built on proprietary mass spectrometry technology. Based in Switzerland, the company provides integrated services and software platforms that enable pharmaceutical companies, biotech researchers, and clinical development teams to measure proteins at unprecedented depth and precision — turning proteomics from a research curiosity into a practical tool for drug discovery and development. Proteins are the workhorses of biology: they carry out virtually every function in a living cell, and understanding how proteins behave — which ones are present, in what quantities, and in what modified forms — is central to understanding disease and identifying therapeutic targets. Mass spectrometry-based proteomics allows researchers to measure thousands of proteins simultaneously from a biological sample, and Biognosys has built its reputation on making that measurement faster, more reproducible, and more accessible than any alternative. The company's software portfolio reflects the breadth of modern proteomics workflows. Spectronaut handles data-independent acquisition (DIA) proteomics, SpectroDive supports targeted protein quantification, SpectroMine addresses data-dependent acquisition (DDA) workflows, and QuiC provides free quality control tools for proteomics datasets. Together, these tools cover the full analytical pipeline from raw mass spectrometry data to biological insight. Biognosys serves clients across the pharmaceutical and biotech value chain, from early target identification through biomarker discovery to clinical trial support and companion diagnostic development. Its growth strategy is built on scientific partnerships and ecosystem development, collaborating with leading academic centers and industry partners to push the boundaries of what proteomics can deliver — and to ensure that Biognosys technology sits at the center of the most important protein measurement projects in life sciences.